关键词：干细胞脐血；胎盘；附脐带血液；造血细胞；遗传性疾病；移植；治疗疾病
摘 要：UCB is the blood that remains in the placenta and the attached umbilical cord after childbirth. Cord blood contains stem cells that are unique, smart, and capable of treating several lifethreatening diseases. They are used in the treatment of hematopoietic and genetic disorders. The placental blood can produce ten times more stem cells compared to the umbilical cord, which can in turn be used for the treatment of an adult patient. The cord blood, which is collected during childbirth, is stored and cryopreserved. The cord blood can be stored at private cord blood banks or public cord blood banks. This preserved blood can be used for transplantation and the treatment of diseases at the later stages of life.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Process of Collection, Processing, and

Storage of Cord Blood Cells

06.1 Donor Evaluation

06.2 Collection Methods

06.3 Processing and Storage Methods

06.4 Sample Retention and Length of Storage

07. Facts: Cord Blood Units

08. US FDA Approved Stem Cell UCB Product

08.1 Hemacord

08.1.1 Mechanism of Action

08.1.2 Side Effects

09. Pipeline Analysis

09.1 Information on Pipeline Candidates

09.1.1 PDA-002

09.1.2 PDA-001

09.1.3 PLX-PAD

09.1.4 PLX-R18

10. Market Landscape

10.1 Market Overview

10.2 Market Size and Forecast

10.3 Five Forces Analysis

11. Market Segmentation by Application

11.1 Cancers

11.2 Blood Disorders

11.3 Metabolic Disorders

11.4 Immune Disorders

11.5 Others

12. Market Segmentation by Storage

12.1 Public Cord Blood Bank

12.2 Private Cord Blood Bank

12.3 Public-Private Cord Blood Banks

13. Harmonization of Biobanking

14. Market Segmentation by End-user

14.1 Research Institutes

14.2 Pharmaceutical Companies

14.3 Biobanks

14.4 Hospitals

15. Geographical Segmentation

15.1 Stem Cell UCB Market in Americas

15.1.1 Market Size and Forecast

15.2 Stem Cell UCB Market in EMEA

15.2.1 Market Size and Forecast

15.3 Stem Cell UCB Market in APAC

15.3.1 Market Size and Forecast

16. Buying Criteria

17. Market Growth Drivers

18. Drivers and their Impact

19. Market Challenges

20. Impact of Drivers and Challenges

21. Market Trends

22. Trends and their Impact

23. Vendor Landscape

23.1 Competitive Scenario

23.1.1 Key News

23.1.2 Mergers and Acquisitions

23.2 Market Share Analysis 2014

23.2.1 Caladrius Biosciences

23.2.2 Celgene Corp

23.2.3 Mesoblast Ltd.

23.2.4 Pluristem Therapeutics

23.3 Other and Future Prominent Vendors

24. Global Stem Cell UCB Market: Key

Takeaways

25. Key Vendor Analysis

25.1 Caladrious

25.1.1 Key Facts

25.1.2 Business Overview

25.1.3 Business Segmentation by Revenue 2014

25.1.4 Business Segmentation by Revenue 2013 and 2014

25.1.5 Geographical Segmentation by Revenue 2014

25.1.6 Business Strategy

25.1.7 Recent Developments

25.1.8 SWOT Analysis

25.2 Celgene

25.2.1 Key Facts

25.2.2 Business Overview

25.2.3 Business Strategy

25.2.4 Business Segmentation by Revenue

25.2.5 Sales by Geography

25.2.6 Key Information

25.2.7 SWOT Analysis

25.3 Mesoblast

25.3.1 Key Facts

25.3.2 Business Overview

25.3.3 Therapeutic Areas

25.3.4 Geographical Segmentation

25.3.5 Business Strategy

25.3.6 Recent Developments

25.3.7 SWOT Analysis

25.4 Pluristem

25.4.1 Key Facts

25.4.2 Business Overview

25.4.3 Geographical Presence

25.4.4 Business Strategy

25.4.5 Recent Developments

25.4.6 SWOT Analysis

26. Other Reports in this Series